Basics

What Is GLP-1? How GLP-1 Receptor Agonists Work for Weight Loss

GLP-1 Companion · 8 min read

If you have been researching weight loss medications, you have almost certainly encountered the term GLP-1. From Ozempic to Wegovy, the class of drugs known as GLP-1 receptor agonists has transformed the landscape of obesity treatment. But what exactly is GLP-1, and how do these medications help people lose weight? This guide breaks it all down in plain language.

What Is GLP-1?

GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone produced naturally by specialized cells in the small intestine, known as L-cells, in response to food intake. When you eat a meal, GLP-1 is released into the bloodstream within minutes and triggers a cascade of metabolic responses that help your body process nutrients and regulate energy balance.

Natural GLP-1 has a very short half-life of about two minutes because it is rapidly broken down by an enzyme called dipeptidyl peptidase-4 (DPP-4). This short lifespan is one reason why scientists developed synthetic versions that last much longer in the body.

What Are GLP-1 Receptor Agonists?

GLP-1 receptor agonists (GLP-1 RAs) are synthetic medications designed to mimic the effects of natural GLP-1 but with a significantly longer duration of action. While your body's own GLP-1 breaks down within minutes, these engineered molecules can remain active for days or even weeks, depending on the specific formulation.

These medications bind to the same receptors as natural GLP-1, activating the same biological pathways but in a more sustained and therapeutically meaningful way. They are administered via subcutaneous injection, typically once weekly, though some older formulations require daily dosing.

How GLP-1 Receptor Agonists Work: The Mechanism of Action

GLP-1 receptor agonists promote weight loss and metabolic improvement through several interconnected mechanisms. Understanding each pathway helps explain why these medications are so effective.

1. Slowing Gastric Emptying

One of the most impactful effects of GLP-1 receptor agonists is the delay in gastric emptying, the process by which food moves from the stomach into the small intestine. When the stomach empties more slowly, you feel full for a longer period after eating. This leads to smaller meal sizes and reduced snacking between meals. Studies show that gastric emptying can be delayed by 20 to 40 percent in patients taking these medications.

2. Reducing Appetite Through Brain Signaling

GLP-1 receptors are found in the hypothalamus and brainstem, regions of the brain that regulate hunger, satiety, and reward-driven eating behaviors. When GLP-1 receptor agonists activate these brain receptors, they reduce appetite at a neurological level. Many patients report that food simply becomes less interesting, and cravings for high-calorie foods diminish substantially.

3. Enhancing Insulin Secretion

GLP-1 receptor agonists stimulate the pancreas to release insulin in a glucose-dependent manner. This means they increase insulin secretion only when blood sugar levels are elevated, which reduces the risk of hypoglycemia (dangerously low blood sugar). This mechanism makes them especially valuable for patients with type 2 diabetes in addition to obesity.

4. Suppressing Glucagon Release

Glucagon is a hormone that tells the liver to release stored glucose into the bloodstream. GLP-1 receptor agonists suppress inappropriate glucagon secretion, which helps keep blood sugar levels stable and reduces the liver's contribution to high blood glucose after meals.

FDA-Approved GLP-1 Medications

Several GLP-1 receptor agonists have received FDA approval for either type 2 diabetes, obesity, or both. The most widely discussed medications in this class include:

• Semaglutide (Ozempic) -- FDA-approved for type 2 diabetes; also demonstrated cardiovascular risk reduction in the SUSTAIN-6 trial.
• Semaglutide (Wegovy) -- FDA-approved for chronic weight management and cardiovascular risk reduction (March 2024). Also approved for liver disease (MASH) in August 2025.
• Oral semaglutide (Rybelsus) -- FDA-approved for type 2 diabetes; recently approved (October 2025) to reduce cardiovascular risk based on the SOUL trial.
• Oral semaglutide pill (Wegovy pill) -- FDA-approved December 2025 for weight management; the first GLP-1 pill for obesity.
• Liraglutide (Saxenda) -- FDA-approved for weight management; requires daily injections; a generic version launched in August 2025.
• Tirzepatide (Mounjaro) -- A dual GLP-1/GIP receptor agonist FDA-approved for type 2 diabetes.
• Tirzepatide (Zepbound) -- FDA-approved for chronic weight management and, since December 2024, for obstructive sleep apnea in patients with obesity.
• Orforglipron (Foundayo) -- FDA-approved April 2026; the first non-peptide oral GLP-1 receptor agonist that can be taken with food, making it the most accessible GLP-1 option to date.
• Dulaglutide (Trulicity) -- FDA-approved for type 2 diabetes with cardiovascular risk reduction benefits.

Who Benefits from GLP-1 Receptor Agonists?

GLP-1 receptor agonists are not for everyone, but they can be life-changing for the right candidates. Generally, these medications are prescribed for adults who meet specific medical criteria.

• Adults with a BMI of 30 or higher (obesity)
• Adults with a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol
• Patients with type 2 diabetes who have not achieved adequate blood sugar control with metformin alone
• Individuals who have not achieved meaningful weight loss through diet and exercise alone

What Kind of Results Can You Expect?

Clinical trials have demonstrated significant weight loss with GLP-1 receptor agonists. In the STEP trials, participants taking semaglutide 2.4 mg (Wegovy) lost an average of 15 to 17 percent of their body weight over 68 weeks. Tirzepatide has shown even greater results in some studies, with average weight loss reaching up to 22 percent of body weight in the SURMOUNT trials.

For a 220-pound individual, a 15 percent body weight reduction translates to approximately 33 pounds lost, which can lead to meaningful improvements in blood pressure, cholesterol, blood sugar, joint pain, and overall quality of life.

Are There Side Effects?

Like all medications, GLP-1 receptor agonists come with potential side effects. The most common are gastrointestinal in nature and often improve over time as the body adjusts to the medication.

• Nausea (the most frequently reported side effect)
• Vomiting
• Diarrhea or constipation
• Abdominal pain
• Decreased appetite
• Headache and fatigue during dose escalation

Serious but rare side effects include pancreatitis, gallbladder problems, and, in animal studies, a risk of thyroid C-cell tumors. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take these medications.

The Bottom Line

GLP-1 receptor agonists represent a major advance in the treatment of obesity and type 2 diabetes. By mimicking a hormone your body already produces, these medications reduce appetite, slow digestion, improve blood sugar control, and lead to clinically meaningful weight loss. If you are considering a GLP-1 medication, speak with your healthcare provider to determine whether it is the right fit for your health profile and goals.

Sources

• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.
• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.